title: Approaches to hepatitis C treatment and cure using NS5A inhibitors.
abstract: Recent progress in the understanding of hepatitis C virus (HCV) biology and the availability of in vitro models to study its replication have facilitated the development of direct-acting antiviral agents (DAAs) that target specific steps in the viral replication cycle. Currently, there are three major classes of DAA in clinical development: NS3/4A protease inhibitors, NS5B polymerase inhibitors, and NS5A directed inhibitors. Several compounds thought to bind directly with NS5A are now in various clinical trial phases, including the most advanced, daclatasvir (BMS-790052), ledipasvir (GS-5885), and ABT-267. While many NS5A-targeted compounds demonstrate picomolar potency, the exact mechanism(s) of their action is still unclear. In the clinic, NS5A HCV inhibitors show promise as important components in DAA regimens and have multifunctionality. In addition to inhibiting viral replication, they may synergize with other DAAs, possibly by modulating different viral proteins, to help suppress the emergence of resistant viruses. Structure-based models have identified target interaction domains and spatial interactions that explain drug resistance for mutations at specific positions (eg, residues 93 and 31) within NS5A and potential binding partners. This review provides, insights into the unique complexity of NS5A as a central platform for multiple viral/host protein interactions, and possible mechanism(s) for the NS5A inhibitors currently undergoing clinical trials that target this nonstructural viral protein.
authors.affiliation: Center for AIDS Research and Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA ; Atlanta Veterans Affairs Medical Center, Decatur, GA, USA.
authors.forename: James J
authors.initials: JJ
authors.lastname: Kohler
authors.affiliation: Center for AIDS Research and Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA ; Atlanta Veterans Affairs Medical Center, Decatur, GA, USA.
authors.forename: James H
authors.initials: JH
authors.lastname: Nettles
authors.affiliation: Center for AIDS Research and Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA ; Atlanta Veterans Affairs Medical Center, Decatur, GA, USA.
authors.forename: Franck
authors.initials: F
authors.lastname: Amblard
authors.affiliation: Center for AIDS Research and Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA ; Atlanta Veterans Affairs Medical Center, Decatur, GA, USA.
authors.forename: Selwyn J
authors.initials: SJ
authors.lastname: Hurwitz
authors.affiliation: Center for AIDS Research and Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA ; Atlanta Veterans Affairs Medical Center, Decatur, GA, USA.
authors.forename: Leda
authors.initials: L
authors.lastname: Bassit
authors.affiliation: Center for AIDS Research and Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
authors.forename: Richard A
authors.initials: RA
authors.lastname: Stanton
authors.affiliation: Center for AIDS Research and Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
authors.forename: Maryam
authors.initials: M
authors.lastname: Ehteshami
authors.affiliation: Center for AIDS Research and Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA ; Atlanta Veterans Affairs Medical Center, Decatur, GA, USA.
authors.forename: Raymond F
authors.initials: RF
authors.lastname: Schinazi
keywords: HCV replication complex; clinical trials; direct acting antivirals (DAAs)